CATALYST BIOSCIENCES
Catalyst Biosciences is a drug discovery and development company. It is creating novel catalytic biopharmaceutical products based on engineered human proteases. It is developing proteases for the treatment of a broad range of diseases with a strong focus on hemostasis and inflammation. It is focused on protease therapeutics to address unmet medical needs in disorders of the coagulation systems.
CATALYST BIOSCIENCES
Industry:
Biotechnology Health Care Life Science Medical Medical Device Pharmaceutical Therapeutics
Founded:
1997-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.catalystbiosciences.com
Total Employee:
11+
Status:
Active
Contact:
+1 650 871 0761
Email Addresses:
[email protected]
Total Funding:
301.31 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API LetsEncrypt WordPress Content Delivery Network Wordpress Plugins Nginx IPv6
Similar Organizations
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Cantel Medical
Cantel Medical is a provider of infection prevention products and services for caregivers, patients, and other healthcare providers.
Vero Biotech
Vero Biotech is a biopharmaceutical company that commercializes inhaled nitric oxide delivery systems for healthcare providers.
Getinge
Getinge identifies customer issues and promotes clinical and economic benefits and follow and support the customer decision process.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Biologics Consulting
Biologics Consulting is a product development consulting firm for biologics, pharmaceuticals, and medical devices.
Thermogenesis
Thermogenesis, a health care company, focuses in development of automated technologies for cell-based therapeutics and bioprocessing.
Asensus Surgical
Asensus Surgical is a medical device company that digitizes the interface between the surgeon and the patient.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Essex Woodlands Healthcare Partners
Essex Woodlands Healthcare Partners investment in Post-IPO Equity - Catalyst Biosciences
HealthCare Ventures
HealthCare Ventures investment in Post-IPO Equity - Catalyst Biosciences
Morgenthaler Ventures
Morgenthaler Ventures investment in Post-IPO Equity - Catalyst Biosciences
Johnson & Johnson Development Corporation
Johnson & Johnson Development Corporation investment in Post-IPO Equity - Catalyst Biosciences
Burrill & Company
Burrill & Company investment in Post-IPO Equity - Catalyst Biosciences
Novartis Venture Fund
Novartis Venture Fund investment in Post-IPO Equity - Catalyst Biosciences
Essex Woodlands Healthcare Partners
Essex Woodlands Healthcare Partners investment in Post-IPO Equity - Catalyst Biosciences
Burrill & Company
Burrill & Company investment in Post-IPO Equity - Catalyst Biosciences
Sofinnova Investments
Sofinnova Investments investment in Post-IPO Equity - Catalyst Biosciences
Morgenthaler Ventures
Morgenthaler Ventures investment in Post-IPO Equity - Catalyst Biosciences
Key Employee Changes
| Date | New article |
|---|---|
| 2021-10-13 | Catalyst Biosciences Announces Chief Financial Officer Transition |
Official Site Inspections
http://www.catalystbiosciences.com Semrush global rank: 2.44 M Semrush visits lastest month: 7.37 K
- Host name: ewhserver1302.edgewebhosting.net
- IP address: 69.63.140.80
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Catalyst Biosciences"
Catalyst Biosciences Completes First Steps in Reverse Merger Plan
Dec 27, 2022 Leadership & Organization Effective with the closing of the F351 acquisition, the Catalyst Board will consist of three legacy Catalyst directors (Augustine Lawlor, Nassim …See details»
Catalyst Biosciences - Crunchbase Company Profile & Funding
Catalyst Biosciences is a research and clinical development biopharmaceutical company. They focus on addressing unmet medical needs in rare disorders of the complement and …See details»
Catalyst Biosciences - LinkedIn
Catalyst Biosciences | 7,094 followers on LinkedIn. Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the ...See details»
Catalyst Biosciences Announces Completion of Business …
Oct 30, 2023 Catalyst Biosciences, Inc. The combined company will operate as “Gyre Therapeutics, Inc.” with its common stock traded on Nasdaq under trading symbol “GYRE” …See details»
Catalyst Biosciences - Overview, News & Similar companies
May 14, 2024 View Catalyst Biosciences (www.catalystbiosciences.com) location in California, United States , revenue, industry and description. ... Nassim Usman, President & Chief …See details»
Catalyst Biosciences - Craft
Catalyst Biosciences is a drug R&D company creating catalytic biopharmaceutical products based on engineered human proteases. The Company uses a scientific approach focused on …See details»
Catalyst Biosciences company profile - Statista
Catalyst Biosciences was founded in 1997 and operates in Wilmington, United States. The company engages in the sector 'Pharmaceuticals, Medicinal Chemical & Botanical Products' …See details»
Catalyst Biosciences Reports Fourth Quarter and Year-end 2021 …
SOUTH SAN FRANCISCO, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the fourth …See details»
Catalyst Biosciences Completes First Steps in Reverse Merger Plan
Dec 27, 2022 Acquires F351, a Phase 3 Drug to Treat Fibrosis Will Acquire Controlling Interest in Continent, a China-Based Commercial Pharma Company, from the GNI Group in …See details»
Catalyst Biosciences Announces Completion of Business
Oct 30, 2023 Catalyst Biosciences Announces Completion of Business Combination With Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock SplitSee details»
Catalyst Biosciences Publishes New Investor Presentation
Aug 1, 2022 Provides Details on Current Board’s Cash Distribution Plan and Efforts to Maximize the Amount of Cash Available for Distribution Company Commits to Distributing $45 Million to …See details»
Catalyst Biosciences Completes First Steps in Reverse Merger Plan
Dec 27, 2022 Leadership & Organization Effective with the closing of the F351 acquisition, the Catalyst Board will consist of three legacy Catalyst directors (Augustine Lawlor, Nassim Usman.See details»
Catalyst Biosciences Announces Global License and - GlobeNewswire
Dec 19, 2019 For more information, please visit www.catalystbiosciences.com. Forward-Looking Statements This press release contains forward-looking statements that involve substantial …See details»
Catalyst Biosciences Announces Appointment of Edward Williams …
Williams served on the board of Biotechnology Innovation Organization (BIO), the National Sales Network, ... For more information, please visit www.catalystbiosciences.com. Forward-Looking …See details»
Protease medicines to catalyse change in complement-targeting …
Catalyst Biosciences has built a protease medicines platform for engineering protease therapeutics designed to correct disease-causing imbalances in biological cascades. The …See details»
Catalyst Biosciences Completes First Steps in Reverse
Dec 27, 2022 Leadership & Organization Effective with the closing of the F351 acquisition, the Catalyst Board will consist of three legacy Catalyst directors (Augustine Lawlor, Nassim …See details»
Catalyst Biosciences Announces Change in Corporate Strategy
Nov 12, 2021 Reports Third Quarter 2021 Operating & Financial Results Company to discontinue MarzAA development; focus on developing its complement portfolio Management …See details»
CATALYST BIOSCIENCES
Acute Respiratory Distress Syndrome (ARDS) A potentially fatal respiratory condition with serious lung injuries © Catalyst Biosciences. Pham et al..See details»
Catalyst Biosciences Announces Appointments of Chief Medical …
In addition to Catalyst’s lead Factor VIIa program, Catalyst has two other next-generation coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical …See details»
Catalyst Biosciences Presents Positive Final Data from its Phase 2b ...
Jun 15, 2020 SOUTH SAN FRANCISCO, Calif., June 15, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced final efficacy and safety data …See details»